Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer

doi:10.1053/gast.1997.v112.pm9024304

Gastroenterology

Volume 112, Issue 2, February 1997, Pages 501-510

https://doi.org/10.1053/gast.1997.v112.pm9024304 Get rights and content

Abstract

BACKGROUND & AIMS: Although tumor necrosis factor (TNF)-alpha possesses a potent antitumor activity, systemic administration of TNF-alpha causes severe side effects. To circumvent this, the efficacy of tumor cell-targeted TNF-alpha gene therapy was investigated.

METHODS: Murine hepatocellular carcinoma (HCC) cells were infected with MNSM-Alb e/p- TNF-alpha retroviruses carrying the murine TNF-alpha gene under the transcriptional control of the murine albumin gene promoter, and antitumor effects induced by TNF-alpha gene transfer were examined in vitro and in vivo.

RESULTS: Although MNSM-Alb e/p-TNF-alpha retrovirally infected HCC cells showed the same in vitro cell growth as parental HCC cells, they lost their tumorigenicity when implanted in syngeneic mice and induced tumor immunity against parental HCCs. The retrovirally infected HCC cells also significantly inhibited the tumorigenicity of previously implanted parental HCCs. Furthermore, intratumoral administration of MNSM-Alb e/p-TNF-alpha retroviruses showed the antitumor effect against established HCCs, resulting in significantly prolonged survival periods. Most importantly, intratumoral implantation of MNSM-Alb e/p-TNF-alpha retroviral- producing cells completely abrogated established HCCs in mice.

CONCLUSIONS: These results indicate the potential efficacy of transferring the TNF-alpha gene via retroviral vectors directly into tumors for gene therapy against HCCs.

(Gastroenterology 1997 Feb;112(2):501-10)

References (0)

Cited by (91)

Induction of Antitumor Response by In Vivo Allogeneic Major Histocompatibility Complex Gene Transfer Using Electroporation
2009, Journal of Surgical Research
Citation Excerpt :
On the other hand, others have attempted to modify tumor cells to enhance tumor antigenicity [17–19]. Several previous studies have demonstrated that transfection of cytokine genes, such as tumor necrosis factor-α [20, 21], interferon-γ (IFN-γ) [22–25], interleukin-2 [26–28], or interleukin-4 [29] into the tumor cells induced an antitumor effect, resulting in tumor regression in animal studies and human trials [30]. In recent reports, new approaches using T-cell receptor gene transfer to exploit allogeneic T-cell repertoires have been investigated [1, 31].
Most malignancies lack tumor-associated antigens, which are recognized by T-lymphocytes through major histocompatibility complex (MHC) molecules, and seem to evade host immunological defense. In this study, we investigated whether allogeneic MHC gene transfer into the low-antigenic tumor might induce cell-mediated immunity, and provide an immunotherapeutic effect in vivo.
Mammary adenocarcinoma cells (MAT B III) originated from an F344 rat (RT1A^l) were transfected with a plasmid DNA encoding RT1A^a (pcMRT1A) in vitro. Cytolytic T-cell response was then evaluated using F344 splenocytes. Furthermore, pcMRT1A–liposome complex was injected into the MAT B III tumors grown in F344 rats, followed by a series of eight electrical pulses with a electroporator, every other d for total of four times. The tumor size and survival of animals were evaluated thereafter.
The expression of RT1A^a on the tumor cells induced cytolytic T-cell response in vitro. Intratumor injection of pcMRT1A-liposome complex followed by in vivo electroporation markedly generated biological response, including increased interferon-γ (IFN-γ) expression and a large number of infiltrated cells in the tumor. Inhibited tumor growth, even complete tumor regression, was observed, resulting in prolonged survival time.
Direct transfer of allogeneic MHC gene into the tumor by in vivo electroporation could induce a cell-mediated immune response against the introduced antigens, resulting in local IFN-γ production. This initial response may bring about the subsequent immunological response even to the unmodified tumor cells through cytokines such as IFN-γ, resulting in the marked tumor regression.
<sup>99m</sup>Tc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression
2006, Nuclear Medicine and Biology
The sodium iodide symporter (NIS) gene could be used as an ideal reporter gene as well as a promising therapeutic gene. ^99mTc-pertechnetate has proven to be more advantageous than ¹³¹I-iodide with respect to image quality, procedure and radiation dose in examination of thyroid uptake and scintigraphy. Herein, we investigated the feasibility of monitoring human sodium iodide symporter (hNIS) gene expression with ^99mTc-pertechnetate in hepatoma cells (MH3924A) following tissue-specific expression.
MH3924A cells were stably transfected with the recombinant retroviral vector, in which hNIS cDNA was driven by murine albumin enhancer/promoter (mAlb) and coupled to hygromycin resistance gene using an internal ribosomal entry site. Functional NIS expression in hepatoma cells was confirmed by an ¹²⁵I⁻ uptake assay. The dynamic uptake and efflux of ^99mTc-pertechnetate was determined both in vitro and in vivo.
The ^99mTc-pertechnetate was up to 254-fold higher in stably transfected MH3924A cells than in wild-type cells. However, the in vitro efflux of ^99mTc-pertechnetate out of recombinant cells was rapid with a half-life of less than 2 min. Further, the in vivo studies yielded clear images and quantitative data of mAlbhNIS-infected tumor xenografts using ^99mTc-pertechnetate and γ camera.
The current study demonstrates enhanced ^99mTc-pertechnetate uptake in hepatoma cells in vitro and in vivo following tissue-specific gene transfer using a recombinant retrovirus with the albumin enhancer/promoter and the hNIS gene. It is feasible to monitor hNIS gene expression noninvasively and quantitatively using conventional γ camera and ^99mTc-pertechnetate.
Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression
2016, Tumor Biology
Experimental radiosurgery in animal models
2016, Neuromethods
Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches
2015, Current Gene Therapy
FBP1 and p27kip1 expression after sciatic nerve injury: Implications for schwann cells proliferation and differentiation
2014, Journal of Cellular Biochemistry

View all citing articles on Scopus

View full text